Live Breaking News & Updates on Gynecology Oncology|Page 5

Stay updated with breaking news from Gynecology oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ETDOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicin ....

United States , United Kingdom , University Of Pennsylvania , City Of , Fiona Simpkins , Timothy Yap , Timothya Yap , Perelman School Of Medicine , Johns Hopkins University , National Cancer Institute , Head Of Clinical Development , Securities Exchange , Exchange Commission , National Institute For Health Research , University Of Texas Md Anderson Cancer Center , Cleveland Clinic Foundation , Institute Of Cancer Research , Aprea Therapeutics Inc , Cooperative Group , University Of Miami , Institute For Personalized Cancer Therapy , Division Of Gynecology Oncology , Therapeutics Discovery Division , Department Of Thoracic Head , Translational Research , Cancer Research Training ,

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways - Aprea Therapeutics (NASDAQ:APRE)

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic ....

City Of , United Kingdom , United States , University Of Pennsylvania , Fiona Simpkins , Timothy Yap , Timothya Yap , Mike Moyer , National Institute For Health Research , Johns Hopkins University , Exchange Commission , Department Of Thoracic Head , Head Of Clinical Development , Institute For Personalized Cancer Therapy , Therapeutics Discovery Division , Cancer Research Training , University Of Texas Md Anderson Cancer Center , Institute Of Cancer Research , Perelman School Of Medicine , Division Of Gynecology Oncology , University Of Miami , National Cancer Institute , Cleveland Clinic Foundation , Translational Research , Aprea Therapeutics Inc , Securities Exchange ,

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer

CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK s poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer. ....

Soult Ukpyolsi , South Korea , Jacquelyn Choi , Canariabio Inc , Gynecology Oncology , Cancer Immunology ,

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination With Niraparib in the Treatment of Recurrent Ovarian Cancer

SEOUL, SOUTH KOREA / ACCESSWIRE / August 8, 2023 / CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the succe. ....

Soult Ukpyolsi , South Korea , Jacquelyn Choi , Canariabio Inc , Bio Inc , Gynecology Oncology , Cancer Immunology ,

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Soult Ukpyolsi , South Korea , Jacquelyn Choi , Canariabio Inc , Bio Announces Enrollment Completion , Recurrent Ovarian , Gynecology Oncology , Cancer Immunology , Acn Newswire ,